Vertex Versus NHS England: Was The Stand-Off Worth It?
Real World Evidence Key To CF Deal
Executive Summary
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?
You may also be interested in...
Stock Watch: The Biotech Departure Lane From Europe
It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.
Vertex Finally Inks Orkambi Deal In England
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
Vertex Trikafta Approved As First Triple Combo For Cystic Fibrosis With $311,503 Price Tag
The US FDA cleared the combination in just three months for patients with the most common genetic mutation. Company sets price above double regimen Symdeko, but in line with trailblazer Kalydeco.